Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Laroprovstat - AstraZeneca

Next Previous
Drug Profile

Laroprovstat - AstraZeneca

Alternative Names: AZD-0780

Latest Information Update: 10 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dogma Therapeutics
  • Developer AstraZeneca; Parexel International; Quotient Sciences
  • Class Amines; Antihyperlipidaemics; Cardiovascular therapies; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Hepatoprotectants; Ketones; Pyridines; Pyrimidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atherosclerosis; Cardiovascular disorders; Dyslipidaemias; Hyperlipoproteinaemia type II

Most Recent Events

  • 24 Feb 2026 AstraZeneca initiates enrolment in a phase I trial for Dyslipidaemias (In volunteers) in the USA (NCT07423598)
  • 20 Feb 2026 AstraZeneca in collaboration with Parexel plans a phase I pharmacodynamic trial in Dyslipidaemia in USA (PO) in February 2026 (NCT07423598)
  • 30 Dec 2025 AstraZeneca completes a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT07216131),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top